Literature DB >> 8964525

Evidence of chronic inflammation in retina excised after relaxing retinotomy for anterior proliferative vitreoretinopathy.

G A Limb1, A H Chignell, H Woon, W Green, C J Cole, D C Dumonde.   

Abstract

BACKGROUND: Epiretinal membranes from eyes with proliferative vitreoretinopathy (PVR) frequently express molecules associated with chronic inflammation. To investigate the extent to which inflammation may compromise the detached retina, we determined the expression of inflammatory molecules in anterior retina removed after relaxing retinotomy for retinal detachment complicated by anterior PVR.
METHODS: Surgical retinal specimens were studied immunohistochemically for the distribution of the vascular cell adhesion molecules VCAM, E-selectin, P-selectin, ICAM and PECAM and for the presence of the cytokine TNF alpha and of T lymphocytes (CD3-positive cells), macrophages (CD68-positive cells) and HLA-DR molecules. The findings were compared with those in control cadaveric retina.
RESULTS: Aberrant expression of ICAM-1 was observed in four of nine retinal specimens from eyes with PVR, whereas its expression in control retinas was confined to the external limiting membrane and ganglion cell layers. PECAM was observed in seven of nine surgical retinal specimens and in four of five controls. E-selectin and P-selectin were expressed within the luminal aspects of four of nine retinal specimens from eyes with PVR, and VCAM was present in three of nine surgical specimens investigated. All cadaveric control retinas were negative for E-selectin and VCAM, whilst one was positive for P-selectin. Staining for TNF alpha was observed within luminal aspects and walls of retinal vessels from eight of nine surgical specimens, but was not seen in any of the cadaveric controls. T lymphocytes and cells expressing the macrophage marker CD68 were identified in two and seven of nine diseased retinas respectively, but not in any of the controls. Cells staining for HLA-DR were observed in eight of nine surgical retinal specimens and in three of five controls.
CONCLUSION: The present findings indicate that retina from eyes with advanced PVR may itself be subject to inflammatory changes, and indicate that the PVR process is not limited to retinal membranes, but involves a more widespread distribution of inflammation than is generally appreciated.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8964525     DOI: 10.1007/bf00430412

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  31 in total

1.  Identification of an inducible endothelial-leukocyte adhesion molecule.

Authors:  M P Bevilacqua; J S Pober; D L Mendrick; R S Cotran; M A Gimbrone
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

Review 2.  Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF).

Authors:  S Akira; T Hirano; T Taga; T Kishimoto
Journal:  FASEB J       Date:  1990-08       Impact factor: 5.191

Review 3.  Inflammation and the formation of epiretinal membranes.

Authors:  C Gilbert; P Hiscott; W Unger; I Grierson; D McLeod
Journal:  Eye (Lond)       Date:  1988       Impact factor: 3.775

4.  Recombinant tumor necrosis factor and immune interferon act singly and in combination to reorganize human vascular endothelial cell monolayers.

Authors:  A H Stolpen; E C Guinan; W Fiers; J S Pober
Journal:  Am J Pathol       Date:  1986-04       Impact factor: 4.307

Review 5.  Interleukin 8 and MCAF: novel inflammatory cytokines inducible by IL 1 and TNF.

Authors:  K Matsushima; J J Oppenheim
Journal:  Cytokine       Date:  1989-11       Impact factor: 3.861

6.  Tumor necrosis factor alpha regulates expression of the major histocompatibility complex class II-associated invariant chain by binding of an NF-kappa B-like factor to a promoter element.

Authors:  U Pessara; N Koch
Journal:  Mol Cell Biol       Date:  1990-08       Impact factor: 4.272

7.  The pathophysiology of proliferative vitreoretinopathy.

Authors:  P Wiedemann; M Weller
Journal:  Acta Ophthalmol Suppl       Date:  1988

Review 8.  Fibrogenic cytokines: the role of immune mediators in the development of scar tissue.

Authors:  E J Kovacs
Journal:  Immunol Today       Date:  1991-01

9.  Intercellular adhesion molecule-1 (ICAM-1) and leukocyte function-associated antigen-1 (LFA-1) expression in human epiretinal membranes.

Authors:  H P Heidenkummer; A Kampik
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1992       Impact factor: 3.117

10.  Macrophages in proliferative vitreoretinopathy and proliferative diabetic retinopathy: differentiation of subpopulations.

Authors:  P Esser; K Heimann; P Wiedemann
Journal:  Br J Ophthalmol       Date:  1993-11       Impact factor: 4.638

View more
  4 in total

1.  Vitreous levels of intercellular adhesion molecule 1 (ICAM-1) as a risk indicator of proliferative vitreoretinopathy.

Authors:  G A Limb; A H Chignell
Journal:  Br J Ophthalmol       Date:  1999-08       Impact factor: 4.638

2.  Tumor necrosis factor-alpha regulates transforming growth factor-beta-dependent epithelial-mesenchymal transition by promoting hyaluronan-CD44-moesin interaction.

Authors:  Eri Takahashi; Osamu Nagano; Takatsugu Ishimoto; Toshifumi Yae; Yoshimi Suzuki; Takeshi Shinoda; Satoshi Nakamura; Shinichiro Niwa; Shun Ikeda; Hisashi Koga; Hidenobu Tanihara; Hideyuki Saya
Journal:  J Biol Chem       Date:  2009-12-04       Impact factor: 5.157

3.  A Mouse Model of Proliferative Vitreoretinopathy Induced by Intravitreal Injection of Gas and RPE Cells.

Authors:  Alison Heffer; Victor Wang; Jayanth Sridhar; Steven E Feldon; Richard T Libby; Collynn F Woeller; Ajay E Kuriyan
Journal:  Transl Vis Sci Technol       Date:  2020-06-05       Impact factor: 3.283

4.  TNF-α signaling regulates RUNX1 function in endothelial cells.

Authors:  Hannah A B Whitmore; Dhanesh Amarnani; Michael O'Hare; Santiago Delgado-Tirado; Lucia Gonzalez-Buendia; Miranda An; Julien Pedron; John H Bushweller; Joseph F Arboleda-Velasquez; Leo A Kim
Journal:  FASEB J       Date:  2020-11-02       Impact factor: 5.834

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.